Mendelian Study Links GLP-1RAs to Reduced Stroke and Alzheimer’s Risk
A new study suggests that glucagon-like peptide-1 receptor agonists may lower the risk of stroke and Alzheimer’s disease across various ancestries.
GLP-1 receptor agonists show potential protective effects against stroke and Alzheimer's disease.
The study analyzed data from over 1.8 million individuals across multiple ancestries.
Further clinical trials are necessary to confirm the therapeutic benefits of GLP-1RAs.
A recent Mendelian randomization study has revealed that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may offer protective benefits against Alzheimer’s disease and various types of strokes. This research, which examined genetic data across diverse ancestry groups, highlights the potential of GLP-1RAs, commonly used for treating type 2 diabetes and obesity, to extend their benefits to neurological health.
The study utilized a two-sample Mendelian randomization approach, analyzing genome-wide association study data from populations of European, East Asian, and African descent. With sample sizes ranging from 3,026 to over 1.8 million participants, the researchers aimed to determine if genetically proxied effects of GLP-1RAs correlate with a reduced risk of stroke and Alzheimer’s disease. This method leverages genetic variations to explore causal relationships, providing valuable insights for future research.
Among European participants, the study identified significant protective associations with any stroke and ischaemic stroke, maintaining statistical significance after adjusting for multiple comparisons. The association with Alzheimer’s disease also showed nominal significance, although it was less robust when analyzed solely within the European cohort. In East Asian participants, similar trends were observed for stroke and Alzheimer’s disease, but these findings did not reach statistical significance. Exploratory analyses in African ancestry participants suggested a protective trend, albeit without statistical confirmation.
When results from different ancestries were combined, the study found protective associations for any stroke, ischaemic stroke, cardioembolic stroke, and Alzheimer’s disease, all meeting the adjusted significance threshold. These findings underscore the potential of GLP-1RAs in reducing the risk of neurological diseases, although they do not definitively establish clinical benefits.
The researchers emphasize the need for further experimental studies and clinical trials to validate the protective effects of GLP-1RAs. Understanding the mechanisms behind these associations is crucial for determining the viability of these medications as treatments for neurological conditions. The study serves as a foundation for future research aimed at exploring the therapeutic potential of GLP-1RAs in brain health.
